IOBT Financial Statements From 2010 to 2024

IOBT Stock  USD 0.89  0.04  4.71%   
IO Biotech financial statements provide useful quarterly and yearly information to potential IO Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on IO Biotech financial statements helps investors assess IO Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting IO Biotech's valuation are summarized below:
IO Biotech does not at this moment have any fundamental measures for analysis.
Check IO Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IO Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . IOBT financial statements analysis is a perfect complement when working with IO Biotech Valuation or Volatility modules.
  
Check out the analysis of IO Biotech Correlation against competitors.
For more information on how to buy IOBT Stock please use our How to Invest in IO Biotech guide.

IO Biotech Company Current Valuation Analysis

IO Biotech's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current IO Biotech Current Valuation

    
  (19.53 M)  
Most of IO Biotech's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IO Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, IO Biotech has a Current Valuation of (19.53 Million). This is 100.14% lower than that of the Biotechnology sector and 100.42% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.12% higher than that of the company.

IO Biotech Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining IO Biotech's current stock value. Our valuation model uses many indicators to compare IO Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IO Biotech competition to find correlations between indicators driving IO Biotech's intrinsic value. More Info.
IO Biotech is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value IO Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About IO Biotech Financial Statements

IO Biotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although IO Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in IO Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on IO Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company was incorporated in 2014 and is based in Copenhagen, Denmark. Io Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for IOBT Stock Analysis

When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.